Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis
| Autor: | W.H. Wilson Tang, Unnikrishnan M. Chandrasekharan, Stanley L. Hazen, Yuping Wu, Sihe Wang, M. Elaine Husni, Zeneng Wang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty lcsh:Diseases of the musculoskeletal system Arginine Hyperlipidemias Comorbidity Dimethylarginines Nitric oxide Arthritis Rheumatoid 03 medical and health sciences chemistry.chemical_compound Risk Factors Internal medicine Hyperlipidemia Prevalence Humans Medicine l-arginine Endothelial dysfunction Rheumatoid arthritis Aged biology Arginase business.industry Middle Aged medicine.disease United States 3. Good health Nitric oxide synthase 030104 developmental biology Endocrinology chemistry Cardiovascular Diseases Hypertension biology.protein Female lcsh:RC925-935 business Asymmetric dimethylarginine Biomarkers Research Article |
| Zdroj: | Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-12 (2018) Arthritis Research & Therapy |
| ISSN: | 1478-6362 |
| DOI: | 10.1186/s13075-018-1616-x |
| Popis: | Background Rheumatoid arthritis (RA) patients are at high risk of developing cardiovascular disease (CVD). In RA, chronic inflammation may lead to endothelial dysfunction, an early indicator of CVD, owing to diminished nitric oxide (NO) production. Because l-arginine is the sole precursor of NO, we hypothesized that levels of l-arginine metabolic products reflecting NO metabolism are altered in patients with RA. Methods Plasma samples from patients with RA (n = 119) and age- and sex-matched control subjects (n = 238) were used for this study. Using LC-MS/MS, we measured plasma levels of free l-arginine, l-ornithine, l-citrulline, l-N G-monomethyl arginine (MMA), asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA). We compared global arginine bioavailability ratio (GABR) (i.e., ratio of l-arginine to l-ornithine + l-citrulline) and arginine methylation index (ArgMI) (i.e., ADMA + SDMA/MMA) in patients with RA vs. control subjects. Plasma arginase activity was measured using a sensitive arginase assay kit. The relationship of l-arginine metabolites and arginase activity to CVD risk factors was evaluated using Pearson’s chi-square test. Results Compared with healthy control subjects, the RA cohort showed significantly lower levels of plasma l-arginine (46.11 ± 17.29 vs. 74.2 ± 22.53 μmol/L, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink